Ryan D. Maynard

This profile gathers the share dealings of Ryan D. Maynard across 2 companies, led by Iovance Biotherapeutics, Inc. and Tvardi Therapeutics, Inc. The record holds 4 filings, for trades running from 31 May 2022 to 12 November 2024.

Market trades split into 1 purchase (€47k) and 1 sale (€2,711). The net balance comes to €44k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 1 share grant and 1 option exercise. 2024 to date brings no purchases and 1 sale.

On 14 November 2024 came the latest disclosure, an option exercise for €349k in Iovance Biotherapeutics, Inc. The most recent open-market purchase was published on 2 June 2022, 1,599 days ago. Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.